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Catheter Ablation for Atrial Fibrillation with Heart Failure
To the Editor: In the Catheter Ablation versus 
Standard Conventional Therapy in Patients with 
Left Ventricular Dysfunction and Atrial Fibrilla-
tion (CASTLE-AF) trial, Marrouche et al. (Feb. 1 
issue)1 found a 46% lower rate of death from any 
cause among patients who were randomly as-
signed to catheter ablation than among those 
who were assigned to medical therapy. One con-
cern in interpreting these results is that the pa-
tients underwent randomization before the run-in 
phase.2,3
During the run-in phase, 18 patients in the 
ablation group and 9 in the medical-therapy group 
were excluded. This process may have affected 
patient assignments and subverted randomiza-
tion. Consequent imbalances that may have had 
an effect on the primary end point include a sig-
nificantly higher proportion of patients in the 
medical-therapy group than in the ablation group 
who had a diagnosis of ischemic cardiomyopa-
thy, who had diabetes mellitus, and who were 
receiving digoxin at baseline.
Ischemic heart disease, diabetes, and a high 
serum digoxin concentration have all been associ-
ated with increased mortality, and no data regard-
ing digoxin dosing or monitoring were reported 
in the article.4,5 Although ischemic heart disease 
and digoxin therapy are known confounding fac-
tors, the possibility of imbalances of unknown 
confounding factors cannot be ruled out.
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To the Editor: In the CASTLE-AF trial, Marrouche 
et al. found that in patients with heart failure and 
atrial fibrillation, catheter ablation was associ-
ated with a lower rate of death and hospitaliza-
tion for worsening heart failure than medical 
therapy. However, the trial design appeared to 
have structural biases favoring catheter ablation.
Patients were enrolled only if they had had no 
previous response to or had had unacceptable 
side effects from antiarrhythmic drugs, or if 
they were not willing to take these drugs. Such 
a protocol essentially predetermined a superior 
outcome with ablation. Also, although they had 
not had a response to antiarrhythmic agents, 
patients who were randomly assigned to medical 
therapy were encouraged to proceed with phar-
macologic rhythm control with the use of class 
IA, class IC, and class III agents, many of which 
can increase mortality among patients with sys-
tolic heart failure.1-4
Such probably futile and possibly risky at-
tempts at rhythm control continued in 30% of 
the patients in the medical-therapy group. More 
appropriate approaches would have been to en-
roll patients regardless of the results of previous 
antiarrhythmic treatment or to randomly assign 
patients in whom antiarrhythmic drugs had not 
worked to catheter ablation or simple rate control.
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To the Editor: Marrouche et al. report the supe-
riority of catheter ablation over medical therapy 
in patients with paroxysmal or persistent atrial 
fibrillation and a left ventricular ejection fraction 
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(LVEF) of 35% or less who had not had a response 
to antiarrhythmic drugs, had unacceptable side 
effects, or were unwilling to take these drugs. 
The presence of implantable cardioverter–defibril-
lators (ICDs) indicates that the patients were 
thought to have irreversible cardiomyopathy 
while they were receiving target or maximally ad-
justed doses of guideline-directed medical ther-
apy for heart failure, including beta-blockers.
Notably, in 68% of the patients in the ablation 
group, the LVEF improved to 35% or higher after 
ablation. Therefore, an astounding number of 
patients appear to have received ICDs prema-
turely or inappropriately, even after the exclusion 
of patients in whom the indication for ICD im-
plantation was secondary prevention and patients 
receiving cardiac resynchronization therapy. Erro-
neous implantation due to poor estimation of the 
adequacy of treatment for atrial fibrillation has 
been reported in a small series.1 The magnitude 
of erroneous ICD implantation observed in this 
randomized, controlled trial is alarming.
Current heart-failure guidelines do not system-
atically address treatment for atrial fibrillation 
before ICDs are recommended.2 The imperative 
need for data, such as the burden of atrial fibril-
lation and the target heart rate, to elucidate this 
nebulous scenario should be a major message 
from this important trial.
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To the Editor: Marrouche and colleagues report 
a significantly lower rate of the composite end 
point with catheter ablation than with medical 
therapy among patients with atrial fibrillation 
and heart failure. A substantial number of pa-
tients were lost to follow-up in the ablation and 
medical-therapy groups (23 of 179 patients [12.8%] 
vs. 10 of 184 patients [5.4%]). In addition, 28 pa-
tients in the ablation group (15.6%) and 18 pa-
tients in the medical-therapy group (9.8%) did not 
receive their assigned intervention.
The fragility index, a statistical measure of 
the robustness of clinical trial results, is the 
minimum number of events that would have to 
be added in the group of patients with the small-
est number of events in order to change a result 
from being significant to not significant (P≥0.05 
by Fisher’s exact test). Higher numbers in the 
fragility index indicate a more statistically ro-
bust result.1-3 The fragility indexes for the end 
points reported in the CASTLE-AF trial range 
from 3 to 11 (Table 1), as compared with a me-
Variable
Ablation 
(N = 179)
Medical Therapy 
 (N = 184)
Fragility 
Index
Primary end point — no. (%)† 51 (28.5) 82 (44.6) 11
As-treated analysis — no./total no. (%)‡      51/169 (30.2)      82/194 (42.3) 3
Per-protocol analysis — no./total no. (%)‡      38/129 (29.5)      71/163 (43.6) 3
Death from any cause — no. (%) 24 (13.4) 46 (25.0) 5
Heart failure–related hospitalization — no. (%) 37 (20.7) 66 (35.9) 10
Cardiovascular death — no. (%) 20 (11.2) 41 (22.3) 6
Cardiovascular hospitalization — no. (%) 64 (35.8) 89 (48.4) 4
*  The fragility index, a statistical measure of the robustness of clinical trial results, is the minimum number of events that 
would have to be added in the group of patients with the smallest number of events in order to change a result from 
being significant to not significant (P≥0.05 by Fisher’s exact test). Higher numbers in the fragility index indicate a more 
statistically robust result.
†  The primary end point is a composite of death from any cause or hospitalization for worsening heart failure.
‡  Details are available in Table S7 in the Supplementary Appendix of the article, available at NEJM.org.
Table 1. Fragility Index for Reported Outcomes.*
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dian fragility index of 26 in other trials involving 
patients with heart failure.2 The small fragility 
indexes, the high proportion of patients lost to 
follow-up, the greater number of patients lost 
to follow-up in the ablation group than the fra-
gility index, and the high crossover rates all call 
into question the validity of the trial findings. 
Caution should be exercised in translating the 
results of this trial into clinical practice without 
further confirmatory evidence.
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The authors and a colleague reply: In re-
sponse to the critiques by Alvarez et al.: the sen-
sitivity analysis on an intention-to-treat basis 
with all events included after enrollment yielded 
a similar hazard ratio (0.62) as those in the per-
protocol analysis (0.64) and the as-treated analy-
sis (0.61), with significant P values in each case 
(Table S7 in the Supplementary Appendix of the 
article). Although the number of primary end-
point events was higher in patients with ischemic 
heart failure, those who received digoxin, and 
those with diabetes, these differences were not 
significant. Furthermore, as shown in Figure 3 
of the article, patients with ischemic cardiomy-
opathy had a significantly lower event rate with 
ablation than with medical therapy (35% vs. 55%; 
P = 0.008 by the chi-square test), which indicates 
that patients with ischemic cardiomyopathy had 
a greater benefit from ablation than those with 
nonischemic cardiomyopathy.
In response to Littmann: until recently, no 
study had shown that ablation improves hard out-
comes in this patient population, including those 
who have not had a response to antiarrhythmic 
drugs. Also, the protocol of the CASTLE-AF trial 
did not mandate the use of antiarrhythmic drugs. 
Only 28% of the patients in the medical-therapy 
group received antiarrhythmic drugs, similar to 
the proportion in the ablation group (29%). In 
fact, most of the patients did not receive any 
antiarrhythmic drugs before or during the trial.
In response to Wang: patients in our trial had 
appropriate indications for a dual-chamber ICD 
or a cardiac resynchronization therapy defibril-
lator at the time of enrollment. In fact, their 
indication for ICD implantation was established 
independently of and before their enrollment in 
the trial. The improvement in LVEF reported in our 
trial is not surprising and has occurred in previ-
ous trials showing significant improvement in 
LVEF and dimensions after catheter ablation of 
atrial fibrillation. Nevertheless, an important les-
son learned from the CASTLE-AF trial is to advo-
cate for catheter ablation in this patient popula-
tion before pursuing device implantation.
In response to Docherty et al.: in the study by 
Walsh et al.,1 almost 400 clinical trials with 
significant results that were published in high-
impact journals were evaluated, and the median 
fragility index in these trials was 8. A quarter of 
them had a fragility index of 3 or less, and in 
more than half of the clinical trials, the number 
of patients lost to follow-up was greater than the 
fragility index. In these types of trials, an analy-
sis such as the Cox proportional-hazards model 
is more suitable, since it takes time into account, 
whereas the fragility index is a binary analysis 
with no consideration of time.
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